EUVIMEDEUVIMED entdecken
Crossref

Ailanthone targets the KMT2A-MEN1 complex to suppress lung metastasis of osteosarcoma

Jinrong Liang, Guanglei Qiao, Yawen Zhang, Ying Yuan, Zimei Liu, Yue Jiang, Yan Zhang, Zhoufeng Deng, Liping Yu, Hongjian Lin, Lijun Ma, Yanli Luo und 4 weitere

Phytomedicine · 2025

DOI: 10.1016/j.phymed.2024.156258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Jinrong Liang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China; Department of Oncology, Sixth Peo…. Hauptthemen laut MEDLINE: Lung Neoplasms, Histone-Lysine N-Methyltransferase, Osteosarcoma, Myeloid-Lymphoid Leukemia Protein. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lung metastasis is the leading cause of death in patients with osteosarcoma (OS), and new drugs are urgently needed. Epigenetic reprogramming is a recently proposed hallmark of malignancy; therefore, targeting epigenetic enzymes might provide a novel therapeutic strategy for OS lung metastasis. We recently reported that ailanthone (AIL), a natural product isolated from the Chinese medicinal plant Ailanthus altissima, inhibits OS cell growth and induces substantial metabolic changes; however, its direct targets remain unclear. PURPOSE: To identify the direct targets of AIL in OS and to explore the effects of AIL on OS lung metastasis in vivo. STUDY DESIGN: Direct target proteins of AIL and downstream signaling pathways were identified in Saos-2 and U-2OS OS cells. The in vivo effects of AIL on OS lung metastasis were investigated using a mouse model. METHODS: A novel surface plasmon resonance-high-performance liquid chromatography-mass spectrometry (SPR-HPLC-MS) assay was used to determine direct targets of AIL in OS. A cellular thermal shift assay, molecular docking analysis, enzyme activity assay, qRT-PCR, western blotting, chromatin immunoprecipitation assay, and reverse tests were performed to confirm the target and downstream pathway of AIL. A tumor xenograft model was used to verify the efficacy and mechanisms in vivo. RESULTS: Histone-lysine N-methyltransferase 2A (KMT2A) together with its scaffold protein menin (MEN1) were identified as direct target proteins of AIL in OS. AIL induced the autophagic degradation of the KMT2A-MEN1 complex. Moreover, AIL inhibited intracellular H3K4 methyltransferase activity and epigenetically inhibited the transcription of genes in the serine biosynthetic pathway (SSP). Furthermore, AIL suppressed OS lung metastasis and downregulated KMT2A, MEN1, and SSP in mouse models. CONCLUSION: This work showed that AIL targets the KMT2A-MEN1 complex and inhibits SSP to suppress OS lung metastasis. Notably, AIL exhibits new mechanisms of action, distinct from those of existing anti-OS drugs. On the basis of these findings, we proposed a novel strategy to treat OS by targeting epigenetic enzymes and cancer metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHistone-Lysine N-MethyltransferaseOsteosarcomaMyeloid-Lymphoid Leukemia ProteinBone NeoplasmsAilanthusAntineoplastic Agents, PhytogenicAnimalsHumansCell Line, TumorMiceMolecular Docking SimulationMice, NudeSignal TransductionMice, Inbred BALB CXenograft Model Antitumor Assays

Stichwörter der Autor:innen

AilanthoneKMT2AMEN1MetastasisOsteosarcomaPHGDH

Substanzen

Histone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China; Department of Oncology, Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shan…
  • Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.
  • Department of Oncology, Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
  • Department of Pathology, Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
  • Shanghai Clinical Research Ward (SCRW), Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China. Electronic address: hhy761104@sjtu.edu.cn.
  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: liuxin_fus…

Zitieren

APA

Liang, J., Qiao, G., Zhang, Y., Yuan, Y., Liu, Z., Jiang, Y., Zhang, Y., Deng, Z., Yu, L., Lin, H., Ma, L., Luo, Y., Zhou, Y., Hu, H., Liu, X., & Zhang, J. (2025). Ailanthone targets the KMT2A-MEN1 complex to suppress lung metastasis of osteosarcoma. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.156258

Vancouver

Liang J, Qiao G, Zhang Y, Yuan Y, Liu Z, Jiang Y, et al. Ailanthone targets the KMT2A-MEN1 complex to suppress lung metastasis of osteosarcoma. Phytomedicine. 2025. doi:10.1016/j.phymed.2024.156258

BibTeX
@article{Liang2025,
  author = {Liang, Jinrong and Qiao, Guanglei and Zhang, Yawen and Yuan, Ying and Liu, Zimei and Jiang, Yue and Zhang, Yan and Deng, Zhoufeng and Yu, Liping and Lin, Hongjian and Ma, Lijun and Luo, Yanli and Zhou, Yan and Hu, Haiyan and Liu, Xin and Zhang, Jianjun},
  title = {Ailanthone targets the KMT2A-MEN1 complex to suppress lung metastasis of osteosarcoma},
  journal = {Phytomedicine},
  year = {2025},
  doi = {10.1016/j.phymed.2024.156258}
}
Kostenlos starten →